$17,236.52 consulting Payment -- Bristol-Myers Squibb to Dr. Matthew Walker
Oncology Physician Receives Substantial Consulting Fee from Bristol-Myers Squibb for Dupixent-Related Services
This page provides a detailed analysis of a $17,236.52 consulting payment from Bristol-Myers Squibb to Dr. Matthew Walker. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $17,236.52 |
| Payment Type | consulting |
| Payment Nature | Consulting Fee |
| Pharmaceutical Company | Bristol-Myers Squibb |
| Physician | Dr. Matthew Walker |
| NPI Number | 1770373007 |
| Physician Specialty | Oncology |
| Location | Worcester, MA |
| Date of Payment | 2025-04-23 |
| Related Drug/Device | Dupixent |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Bristol-Myers Squibb made a $17.2K consulting payment to Matthew Walker, a Oncology specialist in Worcester, MA. The payment was associated with Dupixent. The payment of $17,236.52 to Dr. Matthew Walker from Bristol-Myers Squibb for consulting services is a significant amount for a single engagement. The payment is specifically linked to consulting related to Dupixent, indicating a focus on this particular drug. The payment occurred in April 2025, suggesting a recent or future engagement being reported.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment indicates your doctor may be providing expert advice to pharmaceutical companies on medications like Dupixent. Discuss any concerns about potential influences on your care with your doctor. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For an Oncology specialist, a $17,236.52 consulting fee from a major pharmaceutical company for services related to a specific drug is a high-value engagement, potentially exceeding typical consulting rates for routine advisory roles.
Regulatory Context: Sunshine Act Requirements
Payments to physicians for consulting services are subject to disclosure under the Sunshine Act, requiring transparency regarding financial relationships between healthcare providers and the pharmaceutical industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- consulting-fee
- pharmaceutical-payments
- oncology
- bristol-myers-squibb
- dupixent
- physician-compensation
Understanding consulting Payments
Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.
Frequently Asked Questions About This Payment
What was this $17.2K payment for?
This was a consulting payment of $17.2K from Bristol-Myers Squibb to Matthew Walker, categorized as "Consulting Fee". It was associated with Dupixent. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Matthew Walker accept pharmaceutical money?
Yes, Matthew Walker received this $17.2K payment from Bristol-Myers Squibb. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Matthew Walker's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this consulting payment?
A consulting payment of $17.2K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Matthew Walker's relationship with Bristol-Myers Squibb?
The payment amount is notably high for a consulting fee, especially for a single date. This $17.2K consulting payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment is tied to a specific drug, Dupixent, suggesting specialized consulting.
What should patients do after learning about this payment?
If you are a patient, this payment indicates your doctor may be providing expert advice to pharmaceutical companies on medications like Dupixent. Discuss any concerns about potential influences on your care with your doctor.
What else should I know about this consulting payment?
The reporting of a future payment date (2025) is unusual and warrants further investigation into reporting timelines.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.